Patent · US Active

Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency

US10167454B2 · kind B2 · utility

9Cited by
53References
27Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 9, 2015
Grant dateJan 1, 2019
Priority date
Expiry dateMar 9, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2800/22
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Viral vectors comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis cirrhosis in OTCD patients by administering hOTC.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.